Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Composition: Summary of Findings - QUARTET USA Trial

Page standards status: Informative

Outcome

Sample Size

Result Without Treatment

Result With Treatment (Observed)

Result With Treatment (Calculated)

Effect Estimate

Certainty of Evidence

What this means

Systolic blood pressure at 12 weeks

62 participants, 60 analyzed, 53 without missing data

[No summary statement.]
[No summary statement.]
[No summary statement.]

difference in means -4.5 mm Hg (95% confidence interval -10.82 mm Hg to 1.32 mm Hg)

[No summary statement.]
[No summary statement.]

Diastolic blood pressure at 12 weeks

62 participants, 60 analyzed, 53 without missing data

[No summary statement.]
[No summary statement.]

[Not a proportion.]

difference in means -4.92 mm Hg (95% confidence interval -8.58 mm Hg to 0.27 mm Hg)

[No summary statement.]
[No summary statement.]

Medication Adherence at 12 weeks

62 participants, 53 without missing data

70%

65.6%

46.33%

odds ratio 0.37 (95% confidence interval 0.19 to 2.08)

[No summary statement.]
[No summary statement.]

Hypertension Control at 12 weeks

62 participants, 60 analyzed, 53 without missing data

54.17%

65.52%

77.11%

odds ratio 2.85 (95% confidence interval 0.94 to 8.59)

[No summary statement.]
[No summary statement.]

Add-on Amlodipine at 6 weeks

62 participants, 60 analyzed, 62 without missing data, 22 events

53.33%

18.75%

51.25%

odds ratio 0.92 (95% confidence interval 0.02 to 0.41)

[No summary statement.]
[No summary statement.]

Adverse event free and hypertension control at 12 weeks

62 participants, 53 analyzed, 53 without missing data, 13 events

33.33%

17.24%

29.33%

odds ratio 0.83 (95% confidence interval 0.22 to 3.16)

[No summary statement.]
[No summary statement.]